Frequently Asked Questions about Helixate® FS

Q. Are there contraindications for Helixate® FS?

A. Known intolerance or allergic reactions to components of Helixate® FS, or known allergies to hamster and mouse proteins, may be a contraindication for Helixate® FS. Baby hamster kidney cells are used in the fermentation [5.2 anchor to fermentation] process to grow the recombinant factor VIII. Mouse antibody proteins (monoclonal antibody immunoaffinity chromatography are used in the purification process to remove factor VIII from the fermentation medium.

Back to top

Q. Does Helixate® FS contain albumin?

A. Unlike many other factor VIII concentrates (both plasma-derived and recombinant), Helixate® FS uses sucrose instead of albumin in the final product to stabilize the recombinant factor VIII molecule. However, human albumin is needed to protect and stabilize the recombinant factor VIII protein that is being secreted by the baby hamster kidney cells in the fermentation medium. Most of the albumin is removed during the many purification steps, but a minimal amount of albumin (.007 milligrams/mL) does remain in the product. No albumin is added during the purification or formulation steps.

Back to top

Q. Does the cell culture medium contain any bovine-derived products?

A. The cell culture medium does not contain any proteins derived from animal sources. For example, bovine insulin has been replaced with recombinant insulin.

Back to top

Q. How should Helixate® FS be stored?

A. When stored at refrigerator temperature, 2°–8°C (36°–46°F), Helixate® FS is stable for the period indicated by the expiration date on the label. Storage of lyophilized powder at room temperature (up to 25°C, or 77°F) may be done for twelve months—for example, in home treatment situations. Avoid freezing. Protect from extreme exposure to light.

Back to top

Q. Is Helixate® FS a recombinant product?

A. Helixate® FS is a recombinant factor VIII product manufactured using a baby hamster kidney (BHK) cell line. In the purification and formulation steps for Helixate® FS, the human albumin used as a factor stabilizer in original Helixate® Antihemophilic Factor (Recombinant) has been replaced with sucrose; however, a highly purified plasma protein is still used in the fermentation medium.

Back to top

Q. Is Helixate® FS effective?

A. Yes. Helixate® FS has similar biologic activity to original Helixate® Antihemophilic Factor (Recombinant) and to factor VIII from human plasma. In clinical studies involving previously treated and untreated patients, respectively, 92.7% and 88% of the bleeding episodes resolved with one or two treatments of Helixate® FS.

Back to top

Q. Is Helixate® FS safe?

A. Yes. In clinical studies involving previously treated patients, no inhibitor [5.2 anchor to inhibitor] formation was detected. In clinical studies involving previously untreated patients, 15% developed inhibitors to Helixate® FS. In the Joint Outcome Study, which was conducted to demonstrate the effectiveness of routine prophylaxis for prevention of joint damage in children, the incidence of new inhibitor development was 12.5%.
The most serious adverse reactions to Helixate® FS are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to antihemophilic factor. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Back to top

Q. Is Helixate® FS virally inactivated?

A. Helixate® FS uses a solvent/detergent process designed to help eliminate lipid-enveloped viruses [5.2 anchor to enveloped viruses] (such as HIV, hepatitis B and C, and herpes). Helixate® FS also uses the patented monoclonal antibody (MAb) immunoaffinity chromatography purification process designed to help eliminate viruses. In this process, antibodies specific to a single target protein (such as factor VIII) are placed in a chromatography column. When the solution is passed through the column, the antibodies bind the target protein.

Back to top

Q. How soon after reconstitution must Helixate® FS be administered?

A. Because there is no preservative in the product, Helixate® FS should be administered within three hours of reconstitution.

Back to top

Q. Other than sucrose, what is the purpose of the other excipients in the final formulation of Helixate® FS?

A. Helixate® FS is lyophilized, which means it is rapidly freeze-dried under high vacuum. When a solution is freeze-dried, crystals form. The sodium, chloride, and calcium chloride protect the product during the freeze-drying process, while the glycine and histidine stabilize the crystal matrix.

Back to top

Q. Is Helixate FS indicated for Prophylaxis?

A. Helixate® FS is indicated for routine prophylaxis in children with hemophilia A with no pre-existing joint damage. Helixate® FS was approved for this indication on July 30, 2009.

Back to top

Q. Which clinical trial demonstrated adequate efficacy for Helixate® FS in a prophylactic regimen?

A. This indication was granted by the FDA based on data from a multicenter, randomized, open-label trial was conducted in 65 boys with severe hemophilia A between April 1996 and April 2005. The results of this trial have been published in The New England Journal of Medicine under the title "Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia" Marilyn J. Manco-Johnson, M.D., Thomas C. Abshire, M.D. et al.

Back to top

Q. Are all factor concentrates indicated for prophylaxis?

A. No, not all factor concentrates are indicated for prophylactic use. Read the indications section in the package insert of the product in use to find out whether the product is indicated for prophylaxis

Back to top

Q. What dosage strengths is Helixate FS available in?

A. Helixate FS is available in the following dosage strengths:

  • 250 IU/2.5-mL diluent**
  • 500 IU/2.5-mL diluent**
  • 1000 IU/2.5-mL diluent**
  • 2000 IU/5.0-mL diluent
  • 3000 IU/5.0-mL diluent


Back to top

Next: Glossary »

Important Safety Information

Helixate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Helixate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to antihemophilic factor. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Helixate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

Please see the full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.